Payment overview · 2025
General Payments
$613.46
21 reported records · 5 companies
Healthcare provider profile · identity verified
Khalid A Baig, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FREMONT, CA · NPI 1720199342
Verified facts
What the public records show
CMS Open Payments records show Khalid A Baig, M.D. received $613.46 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $227.32 | 37.1% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $141.36 | 23.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $115.47 | 18.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.18 | 11.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.13 | 10.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $613.46 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $227.32 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $141.36 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.44 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $115.47 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $68.18 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.13 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.65 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 686 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 62 |
| Gabapentin | Gabapentin | 211 | 67 |
| Losartan Potassium | Losartan Potassium | 183 | 56 |
| Metformin Hcl | Metformin Hcl | 169 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 156 | 51 |
| Carvedilol | Carvedilol | 127 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 32 |
| Jardiance | Empagliflozin | 112 | 22 |
| Omeprazole | Omeprazole | 109 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 33 |
| Valsartan | Valsartan | 101 | 27 |
| Farxiga | Dapagliflozin Propanediol | 98 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 26 |
| Furosemide | Furosemide | 94 | 32 |
| Lisinopril | Lisinopril | 93 | 27 |
| Eliquis | Apixaban | 91 | 23 |
| Allopurinol | Allopurinol | 80 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 28 |
| Donepezil Hcl | Donepezil Hcl | 76 | 28 |
| Nifedipine Er | Nifedipine | 76 | 19 |
| Finasteride | Finasteride | 72 | 15 |
| Lactulose | Lactulose | 72 | 30 |
| Cefdinir | Cefdinir | 71 | 54 |
| Alendronate Sodium | Alendronate Sodium | 63 | 19 |
| Atenolol | Atenolol | 61 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 14 |
| Famotidine | Famotidine | 56 | 19 |
| Ozempic | Semaglutide | 56 | suppressed |
| Prednisone | Prednisone | 49 | 30 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 12 |
| Levofloxacin | Levofloxacin | 46 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 13 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 18 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | 11 |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 19 |
| Alprazolam | Alprazolam | 26 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 18 |
| Glipizide | Glipizide | 26 | suppressed |
| Nateglinide | Nateglinide | 26 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 13 |
| Baclofen | Baclofen | 25 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 16 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Topiramate | Topiramate | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 15 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $613.46 · 21 records | Novo Nordisk Inc | JARDIANCE, Kerendia, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error